Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ:IRWD)

3.595 -0.045 (-1.24%)

Delayed Quote Updated: 11:06 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ironwood Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

A Preview Of Ironwood Pharmaceuticals's Earnings ↗

February 14, 2024

Via Benzinga

Chart Of The Day: Ironwood Pharma - Gastrointestinal Products ↗

February 13, 2024

Via Talk Markets

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call

February 01, 2024

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation

January 08, 2024

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Earnings Preview For Ironwood Pharmaceuticals ↗

August 07, 2023

Via Benzinga

Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance

January 08, 2024

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 03, 2024

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio

December 12, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management

November 30, 2023

Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to...

Via Newsfile

Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference

November 21, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Reports Third Quarter 2023 Results

November 09, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call

October 26, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting

October 23, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week

October 16, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

October 05, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023 ↗

September 28, 2023

Via Benzinga

Why Terran Orbital Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

September 19, 2023

Gainers Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares jumped 124.2% to $0.1697 after falling 15% on Monday.

Via Benzinga

Orchestra BioMed, Vital Farms And Other Big Stocks Moving Higher On Tuesday ↗

September 19, 2023

U.S. stocks traded lower on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance

August 08, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call

July 25, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares

June 29, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio

June 16, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old

June 12, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround ↗

June 12, 2023

Ironwood's plan to purchase a smaller biotech should address some issues that have shareholders concerned.

Via The Motley Fool

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

Why Ironwood Pharmaceuticals Stock Bumped Higher Today ↗

May 22, 2023

Investors indicated approval of the company's upcoming $1 billion asset purchase.

Via The Motley Fool

Ironwood Scoops Up Gastrointestinal Diseases Player For $1B ↗

May 22, 2023

Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) has agreed to acquire VectivBio Holding AG (NASDAQ: VECT) for $17.00 per share in an all-cash transaction with an estimated aggregate consideration of...

Via Benzinga

Why Shares of VectivBio Holding Are Up Today ↗

May 22, 2023

A buyout offer by Ironwood Pharmaceuticals lifted the clinical-stage biotech's stock.

Via The Motley Fool

Merger Monday ↗

May 22, 2023

This morning, Chevron announced a deal to acquire PDC Energy for $72 per share in stock.

Via Talk Markets

Why VectivBio Shares Are Surging Monday ↗

May 22, 2023

VectivBio Holding AG (NASDAQ: VECT) shares are trading higher Monday after GI-focused healthcare company Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) agreed to

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.